Literature DB >> 9581873

CBFa(AML/PEBP2)-related elements in the TGF-beta type I receptor promoter and expression with osteoblast differentiation.

C Ji1, S Casinghino, D J Chang, Y Chen, A Javed, Y Ito, S W Hiebert, J B Lian, G S Stein, T L McCarthy, M Centrella.   

Abstract

Organization of the transforming growth factor-beta (TGF-beta) type I receptor (TRI) promoter predicts constitutive transcription, although its activity increases with differentiation status in cultured osteoblasts. Several sequences in the rat TRI promoter comprise cis-acting elements for CBFa (AML/PEBP2alpha) transcription factors. By gel mobility shift and immunological analyses, a principal osteoblast-derived nuclear factor that binds to these sites is CBFa1 (AML-3/PEBP2alphaA). Rat CBFa1 levels parallel expression of the osteoblast phenotype and increase under conditions that promote mineralized bone nodule formation in vitro. Fusion of CBFa binding sequence from the TRI promoter to enhancer-free transfection vector increases reporter gene expression in cells that possess abundant CBFa1, and overexpression of CBFa increase the activity of transfected native TRI promoter/reporter plasmid. Consequently, phenotype-restricted use of cis-acting elements for CBFa transcription factors can contribute to the high levels of TRI that parallel osteoblast differentiation and to the potent effects of TGF-beta on osteoblast function.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  1998        PMID: 9581873

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  14 in total

1.  FOXO1 modulates osteoblast differentiation.

Authors:  Michelle F Siqueira; Stephen Flowers; Rupa Bhattacharya; Dan Faibish; Yugal Behl; Darrell N Kotton; Lou Gerstenfeld; Elizabeth Moran; Dana T Graves
Journal:  Bone       Date:  2011-01-28       Impact factor: 4.398

2.  Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development.

Authors:  J Y Choi; J Pratap; A Javed; S K Zaidi; L Xing; E Balint; S Dalamangas; B Boyce; A J van Wijnen; J B Lian; J L Stein; S N Jones; G S Stein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

3.  Dose-dependent effects of Runx2 on bone development.

Authors:  Shiqin Zhang; Zhousheng Xiao; Junming Luo; Nan He; Josh Mahlios; L Darryl Quarles
Journal:  J Bone Miner Res       Date:  2009-11       Impact factor: 6.741

4.  Stratified control of IGF-I expression by hypoxia and stress hormones in osteoblasts.

Authors:  Thomas L McCarthy; Zhong Yun; Joseph A Madri; Michael Centrella
Journal:  Gene       Date:  2014-01-15       Impact factor: 3.688

Review 5.  Metastatic bone disease: role of transcription factors and future targets.

Authors:  Jitesh Pratap; Jane B Lian; Gary S Stein
Journal:  Bone       Date:  2010-06-01       Impact factor: 4.398

6.  Multiple Cbfa/AML sites in the rat osteocalcin promoter are required for basal and vitamin D-responsive transcription and contribute to chromatin organization.

Authors:  A Javed; S Gutierrez; M Montecino; A J van Wijnen; J L Stein; G S Stein; J B Lian
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

Review 7.  TGF-beta signaling in chondrocytes.

Authors:  Tian-Fang Li; Regis J O'Keefe; Di Chen
Journal:  Front Biosci       Date:  2005-01-01

8.  β-Catenin independent cross-control between the estradiol and Wnt pathways in osteoblasts.

Authors:  Thomas L McCarthy; Caleb B Kallen; Michael Centrella
Journal:  Gene       Date:  2011-02-16       Impact factor: 3.688

9.  Retinoblastoma binding protein-1 (RBP1) is a Runx2 coactivator and promotes osteoblastic differentiation.

Authors:  David G Monroe; John R Hawse; Malayannan Subramaniam; Thomas C Spelsberg
Journal:  BMC Musculoskelet Disord       Date:  2010-05-28       Impact factor: 2.362

10.  Novel links among Wnt and TGF-beta signaling and Runx2.

Authors:  Thomas L McCarthy; Michael Centrella
Journal:  Mol Endocrinol       Date:  2010-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.